Approved indications: In the United States, Fotivda is approved for adults with relapsed or refractory advanced renal cell carcinoma (RCC) who have received two or more prior systemic therapies.

Off-label uses: Tivozanib has been studied in other cancers (such as liver and colorectal cancers), but these uses are not FDA-approved and are not common routine treatments outside of clinical trials.

Efficacy expectations: In its main trial in previously treated advanced RCC, Fotivda delayed cancer growth compared with sorafenib for most patients and produced tumor shrinkage in some; benefits are usually assessed over weeks to a few months with imaging tests.

Comparison to similar drugs: Fotivda works like other VEGFR tyrosine kinase inhibitors used in kidney cancer, with broadly comparable effectiveness in its approved setting and a side-effect profile that many patients and clinicians find manageable, though serious toxicities can still occur.

Typical dosing and how to take it: For most adults with advanced RCC, the recommended dose is 1.34 mg by mouth once daily for 21 days followed by 7 days off, in repeating 28-day cycles, continued as long as it is working and tolerated; patients with moderate liver impairment typically receive 0.89 mg once daily on the same schedule, and there is no established dosing for children.

Administration tips: Take Fotivda at about the same time each day, with a glass of water, with or without food. Swallow the capsules whole; do not open, crush, or chew them. Your care team may check and control your blood pressure, thyroid function, and other labs before and during treatment and may adjust the dose or pause treatment if side effects occur.

Special dosing instructions: Your oncology team may advise holding Fotivda before and after major surgery to reduce risks of bleeding or poor wound healing, and they may change the dose if you develop significant hypertension, protein in the urine, severe diarrhea, or other side effects.

Missed dose: If you miss a dose, take your next dose at the usual scheduled time and do not take two doses at once to make up for the missed one.

Overdose: If you take more Fotivda than prescribed, contact your oncology team or poison control center right away, or seek emergency medical care, and bring the medication container with you if possible.

Common side effects:

• Fatigue, weakness, loss of appetite, nausea, diarrhea, and voice changes (hoarseness) are very common and can range from mild to moderate.
• High blood pressure, low thyroid function, cough, and mouth sores often develop within the first weeks to months and usually require monitoring and sometimes additional medicines or dose changes.

Serious or rare adverse effects: Seek urgent medical care for chest pain, shortness of breath, sudden severe headache, confusion, vision changes, seizures, heavy or unusual bleeding, signs of blood clots (such as leg swelling or sudden trouble breathing), severe abdominal pain, or significantly decreased urine output, as Fotivda can cause bleeding, blood clots, heart problems, kidney injury, liver problems, and rare brain swelling syndromes.

Warnings and precautions: Blood pressure should be well controlled before and during treatment; people with a history of serious bleeding, blood clots, heart failure, stroke, or uncontrolled high blood pressure require extra caution and monitoring. Fotivda can cause fetal harm, so it should not be used during pregnancy, and effective contraception is recommended for all patients with pregnancy potential (and their partners) during treatment and for 1 month after the last dose; breastfeeding is not recommended during treatment or for 1 month after the final dose. Dose reduction is recommended in moderate liver impairment, and use in severe liver disease, severe kidney failure, or in children has not been established.

Overall safety profile: Fotivda has side effects similar to other VEGFR tyrosine kinase inhibitors (notably hypertension, fatigue, diarrhea, and thyroid changes), and while many patients tolerate it reasonably well with monitoring and dose adjustments, life-threatening events are possible.

Side-effect reporting and safety updates: Patients should tell their cancer care team promptly about any new or worsening symptoms; suspected serious side effects can also be reported to the FDA MedWatch program (online or by phone), where ongoing safety information and alerts about Fotivda are maintained.

Drug and supplement interactions: Strong inducers of the liver enzyme CYP3A4 (such as certain seizure medicines and rifampin) and some other prescription drugs and herbal products, including St. John’s wort, can lower Fotivda levels and may make it less effective, so they are generally avoided or used with caution. Because Fotivda can increase bleeding risk and blood pressure, combining it with blood thinners, antiplatelet drugs, NSAID pain relievers, or other medicines that raise blood pressure or affect clotting requires careful monitoring.

Food, alcohol, and procedure interactions: Fotivda may be taken with or without food, but alcohol should be limited or avoided if you have liver problems or if it worsens side effects like dizziness or nausea. Your care team may recommend temporarily stopping Fotivda before major surgery or certain invasive procedures to reduce bleeding and wound-healing complications.

Precautions and conditions needing extra care: Tell your clinician if you have a history of high blood pressure, heart disease or heart failure, stroke, bleeding or clotting problems, thyroid disease, liver disease, kidney problems, or allergies to yellow dye (tartrazine), because these conditions can affect the safety of Fotivda or require dose adjustments and closer follow-up.

Monitoring needs: During treatment, you will typically have regular checks of blood pressure, blood counts, thyroid, liver and kidney tests, and urine protein, and your team may order imaging tests and, in some cases, heart evaluations based on your overall health and symptoms.

Q: What is Fotivda used for?
A: Fotivda is a prescription capsule used in adults to treat advanced kidney cancer (renal cell carcinoma) that has come back or not responded after at least two prior systemic treatments.

Q: How long will I need to stay on Fotivda?
A: Most people take Fotivda in 28-day cycles (21 days on, 7 days off) and continue as long as their cancer is controlled and side effects remain manageable, which is decided by their oncology team using scans, exams, and lab tests.

Q: Can I take Fotivda with food or other medicines?
A: You can take Fotivda with or without food, but you should always review all prescription drugs, over-the-counter medicines, and supplements with your care team because some, especially certain seizure drugs, rifampin, St. John’s wort, blood thinners, and NSAIDs, may interact with it.

Q: What should I do if I miss a dose of Fotivda?
A: If you miss a dose, simply take your next dose at the usual scheduled time and do not double up or take extra capsules to make up for the missed dose.

Q: Is Fotivda safe during pregnancy or breastfeeding?
A: Fotivda can harm an unborn baby and is not recommended during pregnancy or while breastfeeding; effective birth control is advised during treatment and for 1 month after the last dose, and breastfeeding should be avoided during this same period.

Storage: Keep Fotivda capsules in their original labeled container at room temperature (about 68°F to 77°F / 20°C to 25°C), in a dry place away from heat, moisture, and direct light, and out of reach of children and pets; do not store in a pill organizer unless your care team specifically advises it.

Handling: Caregivers should avoid directly touching the capsules when possible, may pour them into the cap or a small cup, and should wash hands before and after handling; pregnant or breastfeeding caregivers should avoid preparing doses.

Disposal: Ask your oncology clinic or pharmacy how to return unused or expired Fotivda; use a medicine take-back program if available and do not flush capsules down the toilet or throw them loose into household trash.